Johannes F E Mann is an expert in Nephrology at Universitätsklinikum Erlangen (Germany). As of October 2026, ScienceLeadR ranks Johannes F E Mann in the top 1% of experts worldwide for Urination Disorders, Renal Insufficiency and Diabetes Mellitus. Johannes F E Mann has authored 263 publications, the most recent in 2026, and is an investigator in 21 clinical trials. SLR score: 1,149 (community average: 125). How the SLR is computed.

LeadR Profile

Johannes F E Mann Universitätsklinikum Erlangen Germany
1 149 ScienceLeadR Reputation 1149
Network Map

Nephrology

Subspecialties: Endocrinology - Cardiology - Transplantation

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1976 - 2026

Source: PubMed

KfH Kuratorium für Dialyse und Nierentransplantation

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 263

Citations

Citations: 38 383 1st author: 39 Last author: 27 Unique author: 8


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant-Level Exploratory Analysis of the Randomised CONFIDENCE Trial.
PMID 42297748 — albuminuria, therapeutics, diabetes mellitus, type 2
Diabetes Obes Metab20260
Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial.
PMID 42246414 — kidney diseases, creatinine, albuminuria, kidney
JAMA Top journal20260
Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.
PMID 42244376 — diabetes mellitus, kidney diseases, creatinine, safety, blood, albuminuria, blood pressure, kidney, odds ratio, therapeutics, mediation analysis, hemodynamics, diabetes mellitus, type 2
Hypertension20260
Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses.
PMID 42233552 — diabetes mellitus, kidney diseases, glomerular filtration rate, mortality, heart failure, heart, cardiovascular diseases, kidney, cardiology, diabetes mellitus, type 2, semaglutide
J Am Coll Cardiol20260
Response to Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial.
PMID 42160608 — diabetes mellitus, semaglutide
Diabetes Care20260

Clinical Studies 21

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 14
N/A 3
Phase 4 3
Phase 2 1

By status:

Completed 15
Terminated 3
Unknown 3

By type:

Interventional 18
Observational 3

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 0
multicentricup10 18

Main Topics

Cohort/Consortium Investigators 1

LeadR Networks

Main global connection map